Search Articles

View query in Help articles search
e.g. mhealth

Search Results (1 to 3 of 3 Results)

Download search results: CSV END BibTex RIS

Web-Based Explainable Machine Learning-Based Drug Surveillance for Predicting Sunitinib- and Sorafenib-Associated Thyroid Dysfunction: Model Development and Validation Study

Web-Based Explainable Machine Learning-Based Drug Surveillance for Predicting Sunitinib- and Sorafenib-Associated Thyroid Dysfunction: Model Development and Validation Study

Sunitinib- and sorafenib-associated thyroid dysfunction are time-varying and underreported adverse drug reactions (ADR). Despite the efficacy of multitargeted tyrosine kinase inhibitors TKI as first- or second-line therapies for solid and hematologic cancers, thyroid dysfunction—especially hypothyroidism—may complicate treatment regimens using sunitinib and sorafenib.

Fan-Ying Chan, Yi-En Ku, Wen-Nung Lie, Hsiang-Yin Chen

JMIR Form Res 2025;9:e67767

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 1

Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial

Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial

There is more rationale to combine sorafenib with TARE than with TACE. First, TARE is better tolerated than TACE, which may allow a higher dose and longer length of therapy with sorafenib. Additionally, sorafenib may be potentially more synergistic with yttrium-90, as antiangiogenic agents potentiate the effects of radiation on tumor regression [27].

Nikhil Chauhan, Janet Bukovcan, Eveline Boucher, David Cosgrove, Julien Edeline, Bonnie Hamilton, Laura Kulik, Fayaz Master, Riad Salem

JMIR Res Protoc 2018;7(8):e11234

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 4

VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials

VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials

Sorafenib is the only systemic therapy shown to confer survival advantages compared with placebo in patients with advanced unresectable HCC. Two phase III randomized controlled trials (RCTs; the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol [SHARP] study and the Asia-Pacific trial) showed significant increases in median overall survival (OS) in patients treated with sorafenib, compared with placebo [7,8].

Val Gebski, Emma Gibbs, Mihir Gandhi, Gilles Chatellier, Aurelia Dinut, Helena Pereira, Pierce KH Chow, Valérie Vilgrain

JMIR Res Protoc 2017;6(2):e17

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 1